Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

Open access
Nogales, Vanesa, Reinhold, William C., Varma, Sudhir, Martinez-Cardus, Anna, Moutinho, Catia, Moran, Sebastian, Heyn, Holger, Sebio, Ana, Barnadas, Agusti, Pommier, Yves, Esteller, Manel·2016·Oncotarget

Abstract

// Vanesa Nogales 1 , William C. Reinhold 2 , Sudhir Varma 3 , Anna Martinez-Cardus 1 , Catia Moutinho 1 , Sebastian Moran 1 , Holger Heyn 1 , Ana Sebio 4 , Agusti Barnadas 4 , Yves Pommier 3 , Manel Esteller 1, 5, 6 1 Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain 2 Genomics and Bioinformatics Group, Developmental Therapeutics Branch, National Cancer Institute, Bethesda, MD, USA 3 Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA 4 Department of Medical Oncology, Hospital de la Santa Ceu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain 5 Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain 6 Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain Correspondence to: Manel Esteller , e-mail: mesteller@idibell.cat Keywords: SLFN11, CpG island methylation, epigenetics, chemoresistance, DNA-damaging agents Received: August 05, 2015 Accepted: November 16, 2015 Published: November 27, 2015 ABSTRACT Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly used cancer chemotherapy drugs, but very few specific molecular and cellular markers predicting differential sensitivity to these agents in a given tumor type have been clearly identified. Epigenetic gene silencing is increasingly being recognized as a factor conferring distinct tumoral drug sensitivity, so we have used a comprehensive DNA methylation microarray platform to interrogate the widely characterized NCI60 panel of human cancer cell lines with respect to CpG methylation status and cisplatin/carboplatin sensitivity. Using this approach, we have found promoter CpG island hypermethylation-associated silencing of the putative DNA/RNA helicase Schlafen-11 (SLFN11) to be associated with increased resistance to platinum compounds. We have also experimentally validated these findings in vitro . In this setting, we also identified the BRCA1 interacting DHX9 RNA helicase (also known as RHA) as a protein partner for SLFN11, suggesting a mechanistic pathway for the observed chemoresistance effect. Most importantly, we have been able to extend these findings clinically, following the observation that those patients with ovarian and non-small cell lung cancer carrying SLFN11 hypermethylation had a poor response to both cisplatin and carboplatin treatments. Overall, these results identify SLFN11 epigenetic inactivation as a predictor of resistance to platinum drugs in human cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.6413

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 169

Metadata

Authors
Nogales, V., Reinhold, W. C., Varma, S., Martinez-Cardus, A., Moutinho, C., Moran, S., Heyn, H., Sebio, A., Barnadas, A., Pommier, Y., & Esteller, M.
Venue
Oncotarget
Published
2015-11-27
Volume
7
Issue
3
Pages
3084-3097
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2179916275
Cited by
169
References
5
FWCI
4.25
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. https://app.cochat.ai/papers/10.18632/oncotarget.6413
The paper
Nogales, V., Reinhold, W. C., Varma, S., Martinez-Cardus, A., Moutinho, C., Moran, S., Heyn, H., Sebio, A., Barnadas, A., Pommier, Y., & Esteller, M. (2016). Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget. https://doi.org/10.18632/oncotarget.6413

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.